<p>在美国与中国暂停关税的一周，全球市场经历了显著的反弹，纳斯达克综合指数和标准普尔 500 指数等主要指数均录得显著涨幅。在这种积极的市场情绪和通胀数据降温的背景下，小型股表现出韧性，标准普尔中型股 400 指数和罗素 2000 指数的持续正回报便是明证。在这样的环境中，识别有前景的小型股需要关注那些具有强大基本面的公司，这些公司能够利用缓解的贸易紧张局势和消费趋势。</p>
<h3>全球十大未被发现的基本面强劲的宝藏股</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.A.S. Dragon Holdings</td>
<td>77.35%</td>
<td>3.64%</td>
<td>7.13%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Changjiu Holdings</td>
<td>NA</td>
<td>11.55%</td>
<td>10.44%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>COSCO SHIPPING International (Hong Kong)</td>
<td>NA</td>
<td>0.57%</td>
<td>18.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saudi Azm for Communication and Information Technology</td>
<td>2.07%</td>
<td>16.18%</td>
<td>21.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Yibin City Commercial Bank</td>
<td>136.61%</td>
<td>11.29%</td>
<td>20.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Hong Leong Finance</td>
<td>0.07%</td>
<td>6.89%</td>
<td>6.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Lee's Pharmaceutical Holdings</td>
<td>13.81%</td>
<td>-0.34%</td>
<td>-27.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Amanat Holdings PJSC</td>
<td>11.28%</td>
<td>31.80%</td>
<td>1.00%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>36.22%</td>
<td>3.96%</td>
<td>-8.49%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Practic</td>
<td>5.21%</td>
<td>4.49%</td>
<td>7.23%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球未被发现的基本面强劲的宝藏股筛选器中的 3193 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏股。</p>
<h2>西陇科学 (SZSE:002584)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 西陇科学有限公司在中国从事化学试剂的研究、开发、生产和销售，市值为 58.5 亿人民币。</p>
<p><strong>运营：</strong> 该公司主要通过销售化学试剂来产生收入。其成本结构包括与研究、开发和生产过程相关的费用。净利润率在最近几个时期显示出波动，反映出运营效率和市场条件的变化。</p>
<p>西陇科学作为化学行业的一个重要参与者，过去一年显示出 108.7% 的显著盈利增长，超过行业平均水平。尽管最近的业绩受到 3890 万人民币一次性损失的影响，但其净负债权益比为 20.9%，反映出良好的财务管理。公司报告 2024 年收入为 78.2 亿人民币，较去年 70.9 亿人民币有所增长，净收入从 2023 年的 3335 万人民币上升至 6177 万人民币，基本每股收益从去年的 0.06 元增加至 0.11 元，展现出其在市场波动中的韧性。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解西陇科学的动态。</li>
<li>查看我们的历史业绩报告，以获取西陇科学过去表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d3b69d2-f899-4f59-9577-08f651b672db/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d3b69d2-f899-4f59-9577-08f651b672db/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 5 月，SZSE:002584 负债权益比</p>
<h2>山东三元生物科技有限公司 (SZSE:301206)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 山东三元生物科技有限公司专注于在中国研发、生产和销售赤藓糖醇和复合糖产品，市值为 61.8 亿人民币。</p>
<p><strong>运营：</strong> 公司的主要收入来源于其食品添加剂业务，产生 671.21 百万人民币的收入。</p>
<p>山东三元生物科技作为一家小型公司，展现出一系列优势和挑战。尽管最近股价波动，但它保持无债务且盈利质量高。在过去一年中，其盈利增长了 45.8%，超过了食品行业的-5.5% 表现，尽管在过去五年中年均下降了 24%。2025 年第一季度，销售额从去年的 191.89 百万人民币下降至 150.2 百万人民币；然而，净收入略微上升至 2491 万人民币，较之前报告的 2425 万人民币有所增加。公司在 2024 年 7 月启动的回购计划中回购了价值 4148 万人民币的股份。</p>
<ul>
<li>在这份健康报告中解锁我们对山东三元生物科技有限公司股票分析的全面见解。</li>
<li>探索历史数据，以跟踪山东三元生物科技有限公司的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dd7f4cb3-bb53-4b1c-821d-820c16bc693c/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dd7f4cb3-bb53-4b1c-821d-820c16bc693c/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 5 月，SZSE:301206 负债权益比</p>
<h2>Leopalace21 (TSE:8848)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Leopalace21 Corporation 在日本从事公寓、共管公寓和住宅的建设、租赁和销售，市值约为 1683.8 亿日元。</p>
<p><strong>运营：</strong> Leopalace21 通过其租赁业务，包括开发活动，产生显著收入，金额为 4169.4 亿日元。老年护理业务为公司的收入流贡献了 137.3 亿日元。</p>
<p>Leopalace21 作为房地产行业的一个重要参与者，面临着过去一年 57.5% 的负盈利增长，与行业平均水平的 17.2% 形成鲜明对比。尽管面临这一挫折，其交易价格低于估计公允价值的 65%，并且预计年均盈利增长为 7.73%。公司的债务状况显著改善，五年内负债权益比从 1716.6% 降至仅 34%。利息支付由 EBIT 覆盖 22 倍，且自由现金流为正，Leopalace21 在其运营中有潜在的恢复和稳定的前景。</p>
<ul>
<li>通过我们的全面健康报告深入了解 Leopalace21 的复杂情况。</li>
<li>了解 Leopalace21 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39af32bd-aed7-4a72-a97b-38af97096675/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39af32bd-aed7-4a72-a97b-38af97096675/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 5 月，TSE:8848 的债务与股本比率</p>
<h2>总结</h2>
<ul>
<li>通过使用我们的筛选器，在这里深入了解 3193 个具有强大基本面的全球未被发现的投资机会。</li>
<li>持有这些公司的股票？在 Simply Wall St 设置您的投资组合，以无缝跟踪您的投资并接收个性化的投资组合表现更新。</li>
<li>使用 Simply Wall St 提升您的投资组合，这是寻求全球市场覆盖的投资者的终极应用程序。</li>
</ul>
<h2>对其他可能性感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>如果您想交易西陇科学，请在专业人士信任的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用，无账户最低要求，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
<p>赞助内容</p>

西陇科学

<p>在美国和中国暂停关税的一周内，全球市场上涨，纳斯达克和标准普尔 500 等主要指数显著上涨。小型股表现出韧性，标准普尔中型股 400 和罗素 2000 指数尤为突出。值得注意的小型股包括 S.A.S. Dragon Holdings、Changjiu Holdings 和西陇科学，这些公司报告了令人印象深刻的盈利增长。尽管 Leopalace21 的盈利增长为负，但其交易价格远低于公允价值，显示出潜在的复苏机会。投资者被鼓励在当前市场环境中探索这些具有强大基本面的未被发现的投资机会</p>

<p>In a week marked by the U.S.-China tariff suspension, global markets experienced a notable rally, with major indices like the Nasdaq Composite and S&amp;P 500 posting significant gains. Amidst this positive sentiment and cooling inflation figures, small-cap stocks have shown resilience as evidenced by the continued positive returns of the S&amp;P MidCap 400 Index and Russell 2000 Index. In such an environment, identifying promising small-cap stocks involves looking for those with strong fundamentals that can capitalize on easing trade tensions and consumer trends.</p>
<div class="lb-trans"><p>在美国与中国暂停关税的一周，全球市场经历了显著的反弹，纳斯达克综合指数和标准普尔 500 指数等主要指数均录得显著涨幅。在这种积极的市场情绪和通胀数据降温的背景下，小型股表现出韧性，标准普尔中型股 400 指数和罗素 2000 指数的持续正回报便是明证。在这样的环境中，识别有前景的小型股需要关注那些具有强大基本面的公司，这些公司能够利用缓解的贸易紧张局势和消费趋势。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals Globally</h3>
<div class="lb-trans"><h3>全球十大未被发现的基本面强劲的宝藏股</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.A.S. Dragon Holdings</td>
<td>77.35%</td>
<td>3.64%</td>
<td>7.13%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Changjiu Holdings</td>
<td>NA</td>
<td>11.55%</td>
<td>10.44%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>COSCO SHIPPING International (Hong Kong)</td>
<td>NA</td>
<td>0.57%</td>
<td>18.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saudi Azm for Communication and Information Technology</td>
<td>2.07%</td>
<td>16.18%</td>
<td>21.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Yibin City Commercial Bank</td>
<td>136.61%</td>
<td>11.29%</td>
<td>20.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Hong Leong Finance</td>
<td>0.07%</td>
<td>6.89%</td>
<td>6.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Lee's Pharmaceutical Holdings</td>
<td>13.81%</td>
<td>-0.34%</td>
<td>-27.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Amanat Holdings PJSC</td>
<td>11.28%</td>
<td>31.80%</td>
<td>1.00%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>36.22%</td>
<td>3.96%</td>
<td>-8.49%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Practic</td>
<td>5.21%</td>
<td>4.49%</td>
<td>7.23%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.A.S. Dragon Holdings</td>
<td>77.35%</td>
<td>3.64%</td>
<td>7.13%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Changjiu Holdings</td>
<td>NA</td>
<td>11.55%</td>
<td>10.44%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>COSCO SHIPPING International (Hong Kong)</td>
<td>NA</td>
<td>0.57%</td>
<td>18.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saudi Azm for Communication and Information Technology</td>
<td>2.07%</td>
<td>16.18%</td>
<td>21.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Yibin City Commercial Bank</td>
<td>136.61%</td>
<td>11.29%</td>
<td>20.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Hong Leong Finance</td>
<td>0.07%</td>
<td>6.89%</td>
<td>6.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Lee's Pharmaceutical Holdings</td>
<td>13.81%</td>
<td>-0.34%</td>
<td>-27.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Amanat Holdings PJSC</td>
<td>11.28%</td>
<td>31.80%</td>
<td>1.00%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>36.22%</td>
<td>3.96%</td>
<td>-8.49%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Practic</td>
<td>5.21%</td>
<td>4.49%</td>
<td>7.23%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3193 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球未被发现的基本面强劲的宝藏股筛选器中的 3193 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏股。</p>
</div><h2>Xilong Scientific (SZSE:002584)</h2>
<div class="lb-trans"><h2>西陇科学 (SZSE:002584)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Xilong Scientific Co., Ltd. engages in the research, development, manufacturing, and sale of chemical reagents in China with a market cap of CN¥5.85 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 西陇科学有限公司在中国从事化学试剂的研究、开发、生产和销售，市值为 58.5 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through the sale of chemical reagents. Its cost structure includes expenses related to research, development, and manufacturing processes. The net profit margin shows fluctuations over recent periods, reflecting changes in operational efficiency and market conditions.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过销售化学试剂来产生收入。其成本结构包括与研究、开发和生产过程相关的费用。净利润率在最近几个时期显示出波动，反映出运营效率和市场条件的变化。</p>
</div><p>Xilong Scientific, a notable player in the chemicals sector, has shown impressive earnings growth of 108.7% over the past year, outpacing industry averages. Despite a CN¥38.9 million one-off loss impacting recent results, their net debt to equity ratio stands at a satisfactory 20.9%, reflecting sound financial management. The company reported revenue of CN¥7.82 billion for 2024, up from CN¥7.09 billion the previous year, with net income rising to CN¥61.77 million from CN¥33.35 million in 2023 and basic earnings per share increasing to CNY 0.11 from CNY 0.06 last year, showcasing its resilience amidst market volatility.</p>
<div class="lb-trans"><p>西陇科学作为化学行业的一个重要参与者，过去一年显示出 108.7% 的显著盈利增长，超过行业平均水平。尽管最近的业绩受到 3890 万人民币一次性损失的影响，但其净负债权益比为 20.9%，反映出良好的财务管理。公司报告 2024 年收入为 78.2 亿人民币，较去年 70.9 亿人民币有所增长，净收入从 2023 年的 3335 万人民币上升至 6177 万人民币，基本每股收益从去年的 0.06 元增加至 0.11 元，展现出其在市场波动中的韧性。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Xilong Scientific.</li>
<li>Review our historical performance report to gain insights into Xilong Scientific's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解西陇科学的动态。</li>
<li>查看我们的历史业绩报告，以获取西陇科学过去表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d3b69d2-f899-4f59-9577-08f651b672db/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/3d3b69d2-f899-4f59-9577-08f651b672db/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002584 Debt to Equity as at May 2025</p>
<div class="lb-trans"><p>截至 2025 年 5 月，SZSE:002584 负债权益比</p>
</div><h2>Shandong Sanyuan BiotechnologyLtd (SZSE:301206)</h2>
<div class="lb-trans"><h2>山东三元生物科技有限公司 (SZSE:301206)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Shandong Sanyuan Biotechnology Co., Ltd. focuses on the R&amp;D, production, and sale of erythritol and compound sugar products in China, with a market cap of CN¥6.18 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 山东三元生物科技有限公司专注于在中国研发、生产和销售赤藓糖醇和复合糖产品，市值为 61.8 亿人民币。</p>
</div><p><strong>Operations:</strong> The company's primary revenue stream is from its Food Additives Business, generating CN¥671.21 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的主要收入来源于其食品添加剂业务，产生 671.21 百万人民币的收入。</p>
</div><p>Shandong Sanyuan Biotechnology, a small cap company, showcases a mix of strengths and challenges. Despite the volatile share price recently, it remains debt-free with high-quality earnings. Over the past year, its earnings grew by 45.8%, surpassing the food industry's -5.5% performance, although there's been a 24% annual decline over five years. In Q1 2025, sales dropped to CNY 150.2 million from CNY 191.89 million last year; however, net income slightly increased to CNY 24.91 million from CNY 24.25 million previously reported. The company repurchased shares worth CNY 41.48 million as part of its buyback program initiated in July 2024.</p>
<div class="lb-trans"><p>山东三元生物科技作为一家小型公司，展现出一系列优势和挑战。尽管最近股价波动，但它保持无债务且盈利质量高。在过去一年中，其盈利增长了 45.8%，超过了食品行业的-5.5% 表现，尽管在过去五年中年均下降了 24%。2025 年第一季度，销售额从去年的 191.89 百万人民币下降至 150.2 百万人民币；然而，净收入略微上升至 2491 万人民币，较之前报告的 2425 万人民币有所增加。公司在 2024 年 7 月启动的回购计划中回购了价值 4148 万人民币的股份。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Shandong Sanyuan BiotechnologyLtd stock in this health report.</li>
<li>Explore historical data to track Shandong Sanyuan BiotechnologyLtd's performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这份健康报告中解锁我们对山东三元生物科技有限公司股票分析的全面见解。</li>
<li>探索历史数据，以跟踪山东三元生物科技有限公司的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dd7f4cb3-bb53-4b1c-821d-820c16bc693c/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/dd7f4cb3-bb53-4b1c-821d-820c16bc693c/chart/debt-equity-history-analysis"/></p>
<p>SZSE:301206 Debt to Equity as at May 2025</p>
<div class="lb-trans"><p>截至 2025 年 5 月，SZSE:301206 负债权益比</p>
</div><h2>Leopalace21 (TSE:8848)</h2>
<div class="lb-trans"><h2>Leopalace21 (TSE:8848)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Leopalace21 Corporation operates in the construction, leasing, and sale of apartments, condominiums, and residential housing in Japan with a market capitalization of approximately ¥168.38 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Leopalace21 Corporation 在日本从事公寓、共管公寓和住宅的建设、租赁和销售，市值约为 1683.8 亿日元。</p>
</div><p><strong>Operations:</strong> Leopalace21 generates significant revenue from its Leasing Business, including development activities, amounting to ¥416.94 billion. The Elderly Care Business contributes ¥13.73 billion to the company's revenue streams.</p>
<div class="lb-trans"><p><strong>运营：</strong> Leopalace21 通过其租赁业务，包括开发活动，产生显著收入，金额为 4169.4 亿日元。老年护理业务为公司的收入流贡献了 137.3 亿日元。</p>
</div><p>Leopalace21, a notable player in the real estate sector, has faced challenges with a negative earnings growth of 57.5% over the past year, contrasting sharply with the industry average of 17.2%. Despite this setback, it trades at an attractive 65% below its estimated fair value and shows promise with forecasted earnings growth of 7.73% annually. The company's debt situation has improved significantly, reducing its debt-to-equity ratio from a staggering 1716.6% to just 34% over five years. With interest payments well covered by EBIT at 22 times coverage and positive free cash flow, Leopalace21 is positioned for potential recovery and stability in its operations.</p>
<div class="lb-trans"><p>Leopalace21 作为房地产行业的一个重要参与者，面临着过去一年 57.5% 的负盈利增长，与行业平均水平的 17.2% 形成鲜明对比。尽管面临这一挫折，其交易价格低于估计公允价值的 65%，并且预计年均盈利增长为 7.73%。公司的债务状况显著改善，五年内负债权益比从 1716.6% 降至仅 34%。利息支付由 EBIT 覆盖 22 倍，且自由现金流为正，Leopalace21 在其运营中有潜在的恢复和稳定的前景。</p>
</div><ul>
<li>Navigate through the intricacies of Leopalace21 with our comprehensive health report here.</li>
<li>Learn about Leopalace21's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的全面健康报告深入了解 Leopalace21 的复杂情况。</li>
<li>了解 Leopalace21 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39af32bd-aed7-4a72-a97b-38af97096675/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/39af32bd-aed7-4a72-a97b-38af97096675/chart/debt-equity-history-analysis"/></p>
<p>TSE:8848 Debt to Equity as at May 2025</p>
<div class="lb-trans"><p>截至 2025 年 5 月，TSE:8848 的债务与股本比率</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Get an in-depth perspective on all 3193 Global Undiscovered Gems With Strong Fundamentals by using our screener here.</li>
<li>Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.</li>
<li>Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过使用我们的筛选器，在这里深入了解 3193 个具有强大基本面的全球未被发现的投资机会。</li>
<li>持有这些公司的股票？在 Simply Wall St 设置您的投资组合，以无缝跟踪您的投资并接收个性化的投资组合表现更新。</li>
<li>使用 Simply Wall St 提升您的投资组合，这是寻求全球市场覆盖的投资者的终极应用程序。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>对其他可能性感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>If you're looking to trade Xilong Scientific, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您想交易西陇科学，请在专业人士信任的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用，无账户最低要求，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

全球市场中的三大未被发现的潜力股